Results 61 to 70 of about 4,502 (185)

Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) [PDF]

, 2018
Lysergic acid diethylamide (LSD) is perhaps one of the best-known psychoactive substances and many structural modifications of this prototypical lysergamide have been investigated. Several lysergamides were recently encountered as “research chemicals” or
Abramson, Abramson, Araneda, Ashby, Babij, Blair, Brandt, Brandt, Brandt, Brandt, Canal, Chemel, Darmani, Darmani, Darmani, Dilly, Dursun, Forster, Fox, Gasser, Gerber, Gogerty, González-Maeso, Gudelsky, Halberstadt, Halberstadt, Halberstadt, Halberstadt, Halberstadt, Halberstadt, Heal, Hintzen, Hoffman, Hofmann, Isbell, Karst, Kim, Kleven, Kraehenmann, Krebs-Thomson, Li, Marona-Lewicka, Martel, Matsumoto, Nakahara, Newman-Tancredi, Nichols, Nichols, Nichols, Nichols, Pokorny, Preller, Rényi, Salmi, Schreiber, Serafine, Sheldrick, Sheldrick, Silva, Stoll, Strassman, Testa, Valle, Vetulani, Vickers, Vollenweider, Wacker, Watts   +67 more
core   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

An ontogenic study of the behavioral effects of chronic intermittent exposure to ayahuasca in mice

Brazilian Journal of Medical and Biological Research
Ayahuasca is a beverage obtained from decoctions of the Banisteriopsis caapi plus Psychotria viridis. In religious contexts, ayahuasca is used by different age groups.
N.F. Correa-Netto, M.Y. Masukawa, F. Nishide, G.S. Galfano, F. Tamura, M.K. Shimizo, M.P. Marcato, J.G. Santos Junior, A. Linardi   +8 more
doaj   +1 more source

1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Frontiers in Psychiatry, 2021
While psychedelics may have therapeutic potential for treating mental health disorders such as depression, further research is needed to better understand their biological effects and mechanisms of action when considering the development of future novel ...
Sylvana Vilca-Melendez, Malin V. Uthaug, Malin V. Uthaug, Julian L. Griffin   +3 more
doaj   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Hemorheological and metabolic consequences of renal ischemia-reperfusion and their modulation by N,N-dimethyltryptamine on a rat model [PDF]

, 2018
K
Bidiga, László, Deák, Ádám, Frecska, Ede, Ghanem, Souleiman, Magyar, Zsuzsanna, Mester, Anita, Nemes, Balázs Áron, Németh, Norbert, Pető, Katalin, Somogyi, Viktória, Tánczos, Bence   +10 more
core   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety

Research
The 5-HT1A receptor is a critical target in the treatment of depression and anxiety. Bufotenine derivatives, such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-hydroxy-N,N-dimethyltryptamine (5-OH-DMT), and 5-hydroxy-N,N,N-dimethyltryptamine—derived
Shu-jie Li, Qing-ning Yuan, Wen-yuan Wu, Zhi-han Chen, Duo Chen, Hong Shan, Qin-yu Chu, Wen Hu, Kai Wu, Tao Liu, Yu-yu Zhu, Li Hou, Jing Zhou, Jia Duan, Jin-ao Duan, H. Eric Xu, Hong-yue Ma   +16 more
doaj   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source